Objective To explore the mechanism of rhubarb in the treatment of bronchial asthma（asthma） by network pharmacology-molecular docking. Methods The main active components and targets of rhubarb were obtained by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform（TCMSP） and SwissTargetPrediction database. GeneCards and DisGeNET databases were used to search potential targets of asthma. The obtained rhubarb component targets and asthma targets were input into Venny2.1 online software to obtain intersection targets for rhubarb in the treatment of asthma. The interaction network diagram of "rhubarb-active component-target-asthma" was drawn by Cytoscape3.9.1 software. Protein-protein interaction（PPI） analysis was performed on the intersection targets. Metascape was used for Gene Ontology（GO） and Kyoto Encyclopedia of Genes and Genomes（KEGG） pathway enrichment analysis.AutoDock1.5.6 software was used to verify the molecular docking between the core components of rhubarb and the target protein. Results A total of 16 effective active components of rhubarb were collected, corresponding to 250 gene targets,8 400 asthma gene targets, and 171 common targets of rhubarb and asthma. PPI results showed that serine/threonine kinase 1（AKT1）, vascular endothelial growth factor A（VEGFA）, catenin beta 1（CTNNB1）, epidermal growth factor receptor（EGFR）, caspase 3（CASP3） and hypoxia inducible factor 1A（HIF1A） in rhubarb were the core targets for the treatment of asthma. GO enrichment analysis obtained 5 274 biological process（BP）, 494 cellular component（CC） and 918 molecular function（MF）; KEGG pathway enrichment analysis yielded 258 signaling pathways. The binding energy of molecular docking results is low. Conclusion Rhubarb treats asthma through multi-component, multi-target and multi-pathway, but its mechanism still needs to be confirmed by further in vitro and in vitro experiments.

目的：观察解毒舒肝片对HBeAg阴性慢性乙肝患者的治疗作用。方法：将60例HBeAg阴性慢性乙肝患者随机分为治疗组和对照组，治疗组32例给予解毒舒肝片，对照组28例给予阿拓莫兰片、五酯滴丸。在0周、12周、24周检测HBV-DNA、ALT、AST水平及进行安全性评价。结果：两组在12周及24周ALT、AST均较治疗前明显下降(p<0.05)。治疗组在12周及24周HBV-DNA较治疗前明显下降(p<0.05)，24周时HBV-DNA下降较对照组明显(p<0.05)。治疗组24周HBV-DNA阴转率为28.12%，对照组为7.14%。结论：解毒舒肝片能够在一定程度上抑制HBeAg阴性慢性乙肝患者HBV-DNA复制，促进肝功能恢复，具有治疗HBeAg阴性慢性乙肝作用，且安全性良好。